Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
Animals
Antineoplastic Agents
/ chemical synthesis
Cell Proliferation
/ drug effects
Colorectal Neoplasms
/ drug therapy
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Drug Screening Assays, Antitumor
Enzyme Inhibitors
/ chemical synthesis
Female
Humans
Mice
Mice, SCID
Molecular Structure
Neoplasms, Experimental
/ drug therapy
Structure-Activity Relationship
Tankyrases
/ antagonists & inhibitors
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
22 07 2021
22 07 2021
Historique:
pubmed:
14
7
2021
medline:
7
10
2021
entrez:
13
7
2021
Statut:
ppublish
Résumé
Constitutive activation of the canonical Wnt signaling pathway, in most cases driven by inactivation of the tumor suppressor APC, is a hallmark of colorectal cancer. Tankyrases are druggable key regulators in these malignancies and are considered as attractive targets for therapeutic interventions, although no inhibitor has been progressed to clinical development yet. We continued our efforts to develop tankyrase inhibitors targeting the nicotinamide pocket with suitable drug-like properties for investigating effects of Wnt pathway inhibition on tumor growth. Herein, the identification of a screening hit series and its optimization through scaffold hopping and SAR exploration is described. The systematic assessment delivered
Identifiants
pubmed: 34255518
doi: 10.1021/acs.jmedchem.1c00800
doi:
Substances chimiques
Antineoplastic Agents
0
Enzyme Inhibitors
0
Tankyrases
EC 2.4.2.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM